1988
The treatment of indolent lymphomas: watchful waiting v aggressive combined modality treatment.
Young R, Longo D, Glatstein E, Ihde D, Jaffe E, DeVita V. The treatment of indolent lymphomas: watchful waiting v aggressive combined modality treatment. Seminars In Hematology 1988, 25: 11-6. PMID: 2456618.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic Combined Chemotherapy ProtocolsCombined Modality TherapyCyclophosphamideDoxorubicinEtoposideEvaluation Studies as TopicHumansLeucovorinLeukemiaLeukemia, Radiation-InducedLymph NodesLymphoma, Non-HodgkinMechlorethamineMethotrexateNeoplasms, Multiple PrimaryNeoplasms, Radiation-InducedPalliative CarePrednisoneProcarbazineRandom AllocationVincristineConceptsAdvanced indolent lymphomaLimited radiation therapyTotal nodal irradiationIndolent lymphomaRadiation therapyModality treatmentInitial treatmentAggressive combined modality therapyCombined modality therapyEvaluable patientsInduction therapyInitial therapyNodal irradiationFirst remissionInitial remissionFrequent relapsesMedian durationModality therapySystemic therapyCombination chemotherapyMedian timeHistologic progressionLonger survivalPatient's diseasePatients
1976
Combined modality treatment of American Burkittapos;s lymphoma
Ziegler J, Devita V, Graw R, Herzig G, Leventhal B, Levine A, Pomeroy T. Combined modality treatment of American Burkittapos;s lymphoma. Cancer 1976, 38: 2225-2231. PMID: 1036716, DOI: 10.1002/1097-0142(197612)38:6<2225::aid-cncr2820380606>3.0.co;2-f.Peer-Reviewed Original ResearchConceptsBurkitt's lymphomaCombined modality treatmentBone marrow autograftsMajor therapeutic goalPrevention of relapseThird remissionFirst remissionIntensive chemotherapyComplete responseModality treatmentInitial treatmentAmerican patientsMarrow autograftsRisk factorsClinical trialsTherapeutic goalsPatientsLymphomaRemissionChemotherapyTreatmentImmunotherapyRelapseRadiotherapyAutograftEffect of Splenectomy on Tolerance to Combination Chemotherapy in Patients With Lymphoma
Ihde D, DeVita V, Canellos G, Young R. Effect of Splenectomy on Tolerance to Combination Chemotherapy in Patients With Lymphoma. Blood 1976, 47: 211-222. DOI: 10.1182/blood.v47.2.211.211.Peer-Reviewed Original ResearchTolerance to combination chemotherapyCombination chemotherapyHodgkin's diseasePlatelet countControl patientsBone marrow lymphomaSplenectomy per seCycles of therapyCycles of treatmentMatched control patientsPortion of patientsEffect of splenectomyHodgkin lymphomaLymphoma patientsInitial treatmentStaging procedureLymphomaTotal doseSplenectomyChemotherapyLeukocyte countHodgkinPatientsLeukocytesPlateletEffect of splenectomy on tolerance to combination chemotherapy in patients with lymphoma.
Ihde D, DeVita V, Canellos G, Young R. Effect of splenectomy on tolerance to combination chemotherapy in patients with lymphoma. Blood 1976, 47: 211-22. PMID: 1244920, DOI: 10.1182/blood.v47.2.211.bloodjournal472211.Peer-Reviewed Original ResearchConceptsTolerance to combination chemotherapyCombination chemotherapyHodgkin's diseasePlatelet countControl patientsBone marrow lymphomaSplenectomy per seCycles of therapyNon-Hodgkin's lymphomaCycles of treatmentMatched control patientsPortion of patientsEffect of splenectomyLymphoma patientsInitial treatmentStaging procedureLymphomaTotal doseSplenectomyChemotherapyLeukocyte countPatientsHodgkinLeukocytesPlatelet